secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-08-14T12:30:19+00:00
Accession:  0001437749-26-027835
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Q2 2026: MIRACLE CR rates 3x control, cash runway into Q1 2027
------------------------------------------------------------------------

- MIRACLE interim data: CR 43% (190 mg/m²) and 36% (230 mg/m²) vs 12% control; CRc 50% and 57% vs 29%.
- Enrollment >80% of 90 patients; data readout Dec 2026-Feb 2027; Part B start 1H 2027.
- Cash $7.3M at June 30 plus $9.3M raised post-quarter; runway into Q1 2027.
- R&D expenses $5.5M in Q2 2026 vs $3.6M YoY; G&A flat at $2.1M.
- No cardiotoxicity observed; ASCO data support cardiac safety profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/0001437749-26-027835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/mbrx20260811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer